Enovis (NYSE:ENOV) Issues FY 2025 Earnings Guidance

Key Points

• Enovis issued updated FY 2025 earnings guidance, projecting EPS between 3.050-3.200 and revenue of $2.2 billion-$2.3 billion, slightly exceeding consensus estimates.
• Several analysts have recently downgraded their price targets for Enovis, with Canaccord Genuity reducing their target from $75.00 to $70.00, while Needham lowered theirs from $64.00 to $57.00.
• Institutional investors hold 98.45% of Enovis's stock, indicating strong institutional interest, with Goldman Sachs increasing their stake by 37.6%.

Enovis (NYSE:ENOV - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 3.050-3.200 for the period, compared to the consensus estimate of 3.028. The company issued revenue guidance of $2.2 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion.

Enovis Stock Down 0.1%

Shares of ENOV traded down $0.03 during midday trading on Friday, reaching $28.49. 1,499,729 shares of the stock were exchanged, compared to its average volume of 1,617,876. Enovis has a 52 week low of $25.47 and a 52 week high of $49.83. The company has a current ratio of 2.25, a quick ratio of 1.32 and a debt-to-equity ratio of 0.53. The company's 50 day moving average is $30.54 and its two-hundred day moving average is $35.23. The company has a market capitalization of $1.63 billion, a P/E ratio of -2.00 and a beta of 1.70.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.05. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. The company had revenue of $564.50 million for the quarter, compared to the consensus estimate of $555.80 million. During the same quarter last year, the company earned $0.62 earnings per share. The firm's revenue for the quarter was up 7.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Enovis will post 2.79 earnings per share for the current year.

Analyst Ratings Changes

ENOV has been the topic of several analyst reports. Canaccord Genuity Group dropped their target price on Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a report on Friday. Needham & Company LLC dropped their price objective on Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a report on Thursday. Wells Fargo & Company lowered their price target on Enovis from $48.00 to $41.00 and set an "overweight" rating on the stock in a research note on Friday. Evercore ISI lowered their price target on Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, JMP Securities lowered their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Enovis has a consensus rating of "Buy" and an average target price of $51.00.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Empowered Funds LLC increased its holdings in shares of Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock valued at $249,000 after acquiring an additional 749 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company's stock valued at $2,363,000 after purchasing an additional 7,072 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company's stock valued at $10,226,000 after purchasing an additional 73,116 shares during the period. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.